EGFR and neoplasm: It was later reported that targeting PD-L1 glycosylation by 2-deoxy-D-glucose (2-DG) combined with EGFR inhibitors reduced tumor size and enhanced anti-tumor immunity mediated by 4-1BB, a glycoprotein receptor belonging to the tumor necrosis factor receptor superfamily, in syngeneic mouse models of TNBC (32).